Cellular senescence, a state of stable exit from the cell cycle, has often been compared with apoptosis as an intrinsic tumour suppressor mechanism. Various triggers induce either phenotype, depending on the cell type and context. As senescent cells are permanently arrested, it was often assumed that senescence was functionally similar to apoptotic cell death, in terms of its effects on tumour suppression and tumour therapy. However, the view that senescence is an end point of a stress response has been considerably revised over the past decade 1 . Senescence has a heterogeneous phenotype in terms of cellular mark ers: multiple markers are required to define senescence with confidence. Senescence typically depends on the p53 and RB pathways, but other effector programmes confer additional layers of regulation. These include telo mere shortening and a persistent DNA damage response, macro autophagy (referred to as autophagy hereafter) and other metabolic alterations, altered protein secretion, and epigenetic gene regulation [2] [3] [4] . These pathways collec tively contribute to the establishment and maintenance of senescent cells and their fitness.
Cellular senescence, a state of stable exit from the cell cycle, has often been compared with apoptosis as an intrinsic tumour suppressor mechanism. Various triggers induce either phenotype, depending on the cell type and context. As senescent cells are permanently arrested, it was often assumed that senescence was functionally similar to apoptotic cell death, in terms of its effects on tumour suppression and tumour therapy. However, the view that senescence is an end point of a stress response has been considerably revised over the past decade 1 . Senescence has a heterogeneous phenotype in terms of cellular mark ers: multiple markers are required to define senescence with confidence. Senescence typically depends on the p53 and RB pathways, but other effector programmes confer additional layers of regulation. These include telo mere shortening and a persistent DNA damage response, macro autophagy (referred to as autophagy hereafter) and other metabolic alterations, altered protein secretion, and epigenetic gene regulation [2] [3] [4] . These pathways collec tively contribute to the establishment and maintenance of senescent cells and their fitness.
The senescenceassociated secretory phenotype (SASP; also known as the senescencemessaging secretome (SMS)), in particular, provides senescent cells with diverse functionality, and the senescence response can have striking cellautonomous and noncellautonomous activities in vivo 5, 6 . Paradoxically, the diverse effects of the SASP include not only tumour suppressive but also tumorigenic aspects. However, there is another twist in the view of the longterm fate of senescent cells, which, similar to apoptotic cells, can be cleared from lesions in some contexts. We have summarized senescence mark ers and senescenceassociated effector programmes in a recent review 4 . Here, we provide an overview of the differ ent roles that senescence has in the development of cancer. We initially focus on the more established cellautonomous role of senescence as a tumoursuppressive mechanism, emphasising the emerging metabolic features of senes cent cells. We then discuss the noncellautonomous activities of senescence, including their functionality in both tumoursuppressive and tumorigenic contexts and their potential impact on the outcome of cancer treat ment. Although the focus of this Review is on analysing senescence in cancer, its implications in other biological contexts are also briefly summarized in BOX 1. Senescence in preneoplasia Cellular senescence was initially described in human diploid fibroblasts (HDFs), which, in contrast to immor talized cells, undergo a 'permanent' proliferative arrest after longterm cell culture in vitro 7, 8 . This replicative senescence is mainly attributed to progressive telomere shortening, which provokes a persistent DNA dam age response and the activation of tumoursuppressive signals, including activation of the p53 and the p16 (also known as INK4A)-RB pathways [9] [10] [11] . In contrast to humans, mice have long telomeres and adult mouse somatic cells often retain telomerase activity, thereby maintaining telomere length 12 . Loss of telomerase activ ity in mice has been shown to suppress tumorigenesis in various tumour models [13] [14] [15] [16] , and telomere attrition induced senescence is implicated in these tumour suppressive effects 17 , although a modest increase in the incidence of spontaneous tumours derived from highly proliferative cells is evident in these mice, possibly owing to increased chromosomal instability 18 .
Warburg effect
A shift in glucose metabolism from mitochondrial oxidative phosphorylation to glycolysis in the presence of ample oxygen.
The tumoursuppressor function of senescence was further reinforced by the discovery of oncogene induced senescence (OIS). OIS was initially described in culture, where the ectopic expression of oncogenic HRASG12V or its downstream effectors paradoxically led to premature senescence [19] [20] [21] . However, in 2005, a series of studies [22] [23] [24] [25] [26] identified senescence in several pre malignant tumours, both in humans and in mice. The loss of tumour suppressors, such as PTEN 23 
, RB 27 , neurofibromin 1 (NF1) 28 and inositol polyphosphate 4phosphatase, type II (INPP4B) 29 , has also been associated with senescence in premalignant tumours.
Therapy-induced senescence
Senescence can also be induced in response to therapy induced genotoxic stress. Although therapyinduced senescence (TIS) was first described in tumour cell lines 30 not long after the discovery of OIS 19 , TIS is a rel atively unexplored area. This is perhaps partly because tumour cells often show a mixed phenotype of apopto sis and senescence when treated with chemotherapeutic agents, whereas HDFs are typically resistant to apop tosis and readily undergo senescence. te Poele et al. 31 showed that TIS was also evident in human breast cancer samples taken from patients who had under gone preoperative neoadjuvant chemotherapy. These tumours tended to be positive for senescenceassociated βgalactosidase (SAβgal) activity and expression of p16, which are widely used markers of senescence, compared with nontreated tumours. Although this study suggested that a senescencelike phenotype can be induced in tumour cells in vivo, the clinical relevance of TIS remains unclear.
The first genetic evidence that senescence induc tion might represent a worthwhile therapeutic goal was shown in an EμMyc mouse model of B cell lym phoma, in which Myc is expressed under an immuno globulin heavy chain enhancerpromoter and therefore restricted to the B cell compartment. Schmitt et al. 32 examined chemotherapeutic efficacy in this model, in EμMyc; Trp53 −/− lymphomas and in EμMyc lym phomas ectopically expressing the antiapoptotic pro tein BCL2 (EμMyc; Bcl2). EμMyc; Trp53 −/− tumours showed a delayed regression followed by recurrence after cyclophosphamide (CTX) treatment. By contrast, EμMyc; Bcl2 tumours, which are resistant to apoptosis, showed no alteration in tumour size and hence appeared not to have responded to CTX. However, the prognosis of these mice was significantly better than the EμMyc; Trp53 −/− mice because the cells in the EμMyc; Bcl2 lym phomas became senescent, although the EμMyc; Bcl2 lymphomas also eventually progressed. p53dependent senescence could also be induced in EμNras G12D ; Bcl2 lymphomas that were treated with chemotherapy 22 and in Mycdriven lymphomas in response to Myc inacti vation 33 . It was also shown that reactivation of endog enous p53 induces senescence in various p53defective tumours, including Mycdriven lymphomas, Hras G12V driven liver cancer, and sarcomas [34] [35] [36] . Although p53 has important roles both in apoptosis and in senescence, these studies suggest that the p53mediated senescence pathway can affect therapeutic outcome, particularly in an apoptosisdefective context. Some of the most rele vant models of TIS in the in vivo setting are summarized in TABLE 1 and reviewed in Senescence and intracellular pathways Mitochondrial metabolism. Recent studies on senescence associated metabolic features have provided insights into cancer biology and therapy. Specific metabolic pro grammes in cells adapt to genetic changes or environmen tal cues. For example, tumour cells often show a shift in glucose metabolism from mitochondrial oxidative phos phorylation to glycolysis, even in the presence of oxygen (the Warburg effect) 40 . Emerging evidence indicates that senescent cells also shift glucose metabolism, but in a way that is distinct from proliferating cancer cells [41] [42] [43] (FIG. 1) .
Kaplon et al. 41 recently showed that increased mito chondrial oxidative phosphorylation is crucial for the induction of OIS. Pyruvate is at the node between gly colysis and the mitochondrial tricarboxylic acid (TCA) cycle. Pyruvate can be converted by the pyruvate dehy drogenase (PDH) complex to acetylCoA, which enters the TCA cycle (FIG. 1) . Cells in culture expressing either oncogenic BRAFV600E or RASG12V that undergo OIS have increased PDH activity 41 . Downregulation of PDH activity abrogated BRAFV600Einduced senes cence, whereas activation of PDH was sufficient for senescence induction in normal cells, indicating a key role for PDH in OIS. A similar increase in mitochondrial metabolism, resulting in increased oxygen consumption,
Box 1 | Consequences of cellular senescence: aging and development
Besides its role in tumour suppression and tumorigenesis, cellular senescence has been linked to other processes, including aging and, most recently, mammalian embryonic development.
Aging
The functional role of cellular senescence in organismal ageing is not entirely clear. On the one hand, accumulation of several senescence markers in aged individuals has been reported in various tissues 56 . On the other hand, the inverse correlation between the replicative lifespan of cells (such as skin fibroblasts) in culture and donor age seems to be controversial 144 . Thus, ageing affects senescence, but how about the other way around? Compelling evidence for the functional relevance of senescence in ageing has been shown in mice, in which age-dependent accumulation of p16-positive cells in tissue stem cell or progenitor cell compartments contributes to tissue degeneration, and p16 depletion attenuates some age-dependent phenotypes [145] [146] [147] . Interestingly, selective killing of those p16-expressing cells in a premature-ageing mouse model also delays ageing phenotypes 148 . Importantly, unlike p16 ablation, elimination of p16-expressing cells does not facilitate tumorigenesis in this model. It is possible that the efficient turnover of stem or progenitor cells facilitates tissue regenerative capacity. It is also possible that ablation of the senescent cells attenuates the local and perhaps systemic effects of the senescence-associated secretory phenotype (SASP), which might contribute to various aspects of ageing.
Embryogenesis
Two studies have recently uncovered a physiological function for senescence during mammalian embryonic development. Embryonic cell senescence is p21-dependent but not p53-dependent, is accompanied by the SASP, and these cells are eliminated by macrophages 149, 150 . Thus, similar to apoptosis, senescence also contributes to embryonic patterning. Another study identified senescence in normal placenta, in which cell fusion, mediated by the highly fusogenic glycoprotein endogenous retrovirus group W member 1 (ERVWE1), provides the maternal-fetal interface 151 . This study showed that ERVWE1-mediated cell fusion induces senescence. Thus, senescence, which was long thought to purely be a stress response, also seems to be physiologically programmed.
NADPH
The reduced form of NADP + and a source of reducing equivalents. Major sources of NADPH include the pentose phosphate pathway, NADP-dependent malic enzymes and NADP-dependent isocitrate dehydrogenase.
energy production, lipid catabolism and levels of reactive oxygen species (ROS), was found in TIS of EμMyc; Bcl2 lymphomas 43 . These studies highlight the stark contrast between senescent and proliferating tumour cells with respect to the pyruvate flux into the TCA cycle for efficient energy production (FIG. 1) . Interestingly, activation of PDH in mutant BRAFdriven human melanoma cells not only blocks tumorigenesis but also sensitizes them to the BRAF inhibitor PLX4720 (an analogue of vemurafenib), eliminating treatmentresistant cell populations 41 . This finding is encouraging, because although the ATP competitive BRAF inhibitors vemurafenib and dabrafenib have shown marked effects on BRAFV600Edriven mel anomas in the clinic, this response is almost inevitably temporary 44 . Thus, developing combination therapies with BRAF inhibitors and drugs that activate PDH might be a promising strategy. PDH is negatively regulated through phosphorylation by PDH kinase (PDK). PDK1, which is one of four known PDK isozymes, is downreg ulated in BRAFV600Einduced senescence, and RNA interference (RNAi) against PDK1 induces sensitivity of the BRAFV600Eexpressing cells to vemurafenib 41 . Dichloroacetate, a small molecule inhibitor of PDK, has been used in humans for the treatment of lactic acidosis and inherited mitochondrial diseases for decades, and it has already been implicated in cancer therapy 45, 46 . In theory, this drug could be used to inhibit PDK and hence activate PDH in melanoma, but would all melanomas respond to this therapy?
Interestingly, recent studies have identified two dis tinct subgroups in human melanoma: a conventional gly colytic group and a group that is characterised by high rates of oxidative phosphorylation 47, 48 . In the latter group, microphthalmiaassociated transcription factor (MITF), the oncogenic melanocyte lineagespecification tran scription factor, drives peroxisomeproliferatoractivated receptorγ coactivator 1α (PGC1α) expression 47, 48 , and about 10% of human melanomas had an above average expression level of PGC1α 48 . PGC1α is a transcriptional coactivator and promotes mitochondrial respiration and, at the same time, induces many ROSdetoxifying enzymes 49 . Consistently, MITF and PGC1αexpressing melanoma cells are more resistant to oxidative stress. Importantly, no correlation was observed between PGC1α expression and BRAF mutation status 48 . Thus, it would be important to carefully validate the effect of PDK1 inhibition, with or without BRAF inhibitors, in the MITF and PGC1αexpressing subset of melanomas, which seem to be associated with a poor prognosis 47, 48 .
Other metabolic pathways, such as the p53mediated regulation of malic enzymes, have been implicated in the regulation of senescence. Malic enzyme 1 (ME1) and ME2 expression is repressed by p53 and the malic enzymes negatively regulate p53; thus, depletion of the malic enzymes results in p53 activation in a feedforward manner, thereby inducing senescence 50 (FIG. 1 ). However, it is possible that malic enzyme depletionassociated meta bolic alterations also regulate senescence. Malic enzymes catalyse the oxidation of malic acid into pyruvate, using NADP + or NAD and NADP + as cofactors. Malic enzymes are a major source of NADPH for the antioxidant system and lipid biosynthesis, and they have also been implicated in increased glutamine consumption in tumours 51 . Thus, malic enzymes can potentially divert the TCA cycle inter mediate malic acid to the synthesis of macromolecules to form building blocks. Jiang et al. 50 showed that depletion of malic enzymes induces senescence with the reduction of the NADPH levels. Consistently, these cells also show ROS induction and reduced lipid synthesis. In addition, although mitochondrial respiration was not tested in this context, a reduction in malic enzyme activity may facili tate TCA cycle flux by reducing the malate shunt, thereby reinforcing senescenceassociated PDH activation (FIG. 1) . Interestingly, ME2 depletion also induces differentiation in K562 erythroleukaemia cells 52 . Although the role of the malic enzymes in the context of OIS and TIS is still unclear 50 , these studies all seem to point to a senescence associated metabolic shift towards maximal energy pro duction at the expense of macromolecule synthesis and 'reducing power' .
Consistent with this view, Quijano et al. 53 showed that HRASG12Vinduced senescent HDFs exhibit reduced lipid synthesis and increased fatty acid oxidation, lead ing to increased mitochondrial oxygen consumption. As Dörr et al. 43 suggest, such a diversion into energy pro duction would also be beneficial for supporting energy consuming activities in senescent cells, such as producing high levels of secretory proteins (as evident in SASP) and autophagy (see below). Indeed, Quijano et al. 53 showed that the inhibition of fatty acid oxidation in OIS cells results in a reduced production of many SASP compo nents. Unlike rapidly proliferating tumour cells, senescent cells would not need a continuous supply of macromol ecules, such as lipids and nucleotides. Hence, it would
Box 2 | PTEN loss-induced cellular senescence
Among the senescence that is induced by the loss of tumour suppressors, PTEN loss-induced cellular senescence (PICS) in prostatic intraepithelial neoplasia (PIN) has been extensively studied by Pandolfi and colleagues 38, 152 . Pten heterozygosity promotes tumour initiation and proliferation in the prostate but, paradoxically, the complete loss of Pten can oppose prostate tumorigenesis by triggering a powerful p53-dependent cellular senescence response 38 . Consistently, most patients with prostate cancer at presentation have lost one allele of PTEN while maintaining intact TP53, whereas TP53 mutations and the complete loss of PTEN are both associated with advanced stage prostate cancer 153, 154 . Alimonti et al. 152 demonstrated a proof of principle that pharmacological inhibition of PTEN in prostate cancer that is wild type for TP53 results in the inhibition of tumorigenesis with senescence induction in a human xenograft tumour in mice. As PTEN is a negative regulator of the PI3K-mTOR pathway, which is also often considered to be a target for cancer therapy, targeting PTEN may seem to be counterintuitive. Interestingly, upregulation of TP53 upon PTEN inhibition seems to be dependent on mTOR activity, which increases TP53 translation 152 . Thus, in some specific cases, such as tumours in which one allele of PTEN has become inactive, PTEN inhibitors might be an option for cancer therapy. Of note, unlike oncogene-induced senescence (OIS), PICS occurs in the absence of transient hyperproliferation and a DNA damage response (DDR) 152 . As discussed in the main text, pro-senescence treatment may provoke a tumorigenic microenvironment through the senescence-associated secretory phenotype (SASP) in some contexts. The SASP, however, has been shown to be mostly regulated through a persistent DDR 96 . Thus, PICS might provide a unique opportunity to separate pro-senescence therapy from the potential side effects that are derived from the SASP. It would be interesting to know whether PICS, which has been shown not to be associated with DDR, is accompanied by some type of SASP and, if so, how it affects the tumour microenvironment.
be interesting to know whether the reduced capacity for building block production during senescence is a conse quence or a cause of the phenotype. In addition, increased ROS levels due to hyperactive mitochondrial respiration, as well as reduced levels of NADPH, are also likely to con tribute to the induction of senescence, further suggesting the robust involvement of a metabolic shift in senescence.
In contrast to these recent studies, which suggest the highly active state of mitochondrial respiration during OIS and TIS, early studies had associated senescence with mitochondrial dysfunction 54 , particularly in the contexts of ageing and replicative senescence 55, 56 . Although it was recently shown that the metabolic profiles of HDFs undergoing OIS and replicative senescence are highly distinct 53 , inefficient mitochondrial energy produc tion was also observed in the OIS model 57 . The reason for the apparent discrepancy is not clear. However, the dysfunctional mitochondria in HDFs that have under gone OIS or replicative senescence were accompanied by active mitochondrial biogenesis 55, 57 , with a concur rent upregulation of PGC1α 57 , which is a major regulator of mitochondrial biogenesis, thereby increasing respi ration, antioxidant defences and fatty acid oxidation 49 . Interestingly, they also noted increased mitochondrial mass at the perinuclear region 57 , where autophagy (the machinery for the bulk degradation of macromolecules and organelles) is often activated upon stress [58] [59] [60] . These data suggest the potential of active mitochondrial turno ver in OIS cells. Interestingly, it was shown that inefficient mitophagy is associated with mitochondrial dysfunction in some tumour cells 61 . As we discuss below, autophagy can be induced during OIS 59 , and it can cause differ ent effects on the senescence phenotype during OIS, depending on the level of its induction 62 . In addition, the intensity of the oncogenic stress also has a marked effect on the dynamics of the proliferative and senescence responses 63 . Shifting the fine balance between mitochon drial biogenesis and recycling might, at least in part, explain the phenotypic heterogeneity.
Autophagy. Autophagy is a genetically regulated cata bolic process in which cytoplasmic components, includ ing organelles, proteins and other macromolecules, are encircled by autophagic vesicles and are delivered to lys osomes for bulk degradation. Autophagy occurs both basally and in response to metabolic or other stresses 64 . Autophagy has key roles in ageing and cancer, but its links to senescence are only just emerging 65 . The role of autophagy in cancer is multifactorial and highly contextdependent 66, 67 . Autophagy is recognized as a survival factor for tumour cells under metabolic and therapeutic stresses 66, 68 . However, genetic evidence also suggests tumoursuppressive roles for autophagy [69] [70] [71] [72] . Increased autophagic activity during senescence has been shown in different models 4, 73 . SAβgal is a lysoso mal enzyme 74 and is frequently expressed in senescent cells that have autophagic vesicles 58, 75 , suggesting that autophagy might be an integrated part of the senescence programme. Its functional role in senescence, however, seems to differ depending on the experimental system 65 . Autophagy is dynamically activated during OIS and facilitates the synthesis of interleukin6 (IL6) and IL8, which are major components of the SASP 58, 59 . A positive correlation between autophagy and senescence has also been observed in other models, including OIS and TIS in culture, where the inhibition of autophagy often delays the induction of senescence [76] [77] [78] [79] [80] [81] [82] . Consistent with its cyto protective function, blocking autophagy during senes cence induction can also result in cell death 83 or even in the exacerbation of senescence 62, 84 . One speculative explanation for this apparent discrepancy would be that, in addition to the role of autophagy on senescence effec tors (for example, the SASP), its cytoprotective effect could divert the stress response towards senescence rather than cell death. Thus, the outcome of autophagy deficiency in prosenescence conditions may be senes cence bypass if cellular fitness has already been secured, or otherwise a severe reduction of cellular fitness: thus, autophagy might affect the 'quality' of senescence.
Although data on the roles of autophagy in senes cence in vivo are relatively limited 43, 59 , in their EμMyc; Bcl2 model, Dörr et al. 43 recently showed that activated autophagy has a prosurvival role, protecting against proteotoxic stress, which is associated with an increased production of SASP components during TIS. Thus, in contrast to the OIS model in culture, autophagy inhibi tion results in the selective killing of tumours owing to endoplasmic reticulum stress in this context.
Although most studies have indicated that inhibition of autophagy is beneficial for cancer patients (reviewed in REFS 85, 86) , this is not always the case. Rosenfeldt et al. 87 recently investigated the role of autophagy at dif ferent stages of Kras G12D driven pancreatic tumorigenesis. Kras G12D mice develop pancreatic intraepithelial neoplasias (PanINs), which express markers of senescence 24 ; how ever, these lesions can eventually progress to pancreatic ductal adenocarcinoma (PDA). In this model, autophagy deficient mice show a marked but transient accumulation of early PanIN accompanied by increased rates of apop totic cell death, and these lesions never progress to late stage PanINs or PDA 87 . Thus, autophagy seems to have a cytoprotective role in this setting. However, the same study showed that when Kras G12D driven PDA develop ment is accompanied by loss of Trp53 (and is therefore senescencedefective), autophagy deficiency instead accelerated tumour progression. Autophagydeficient cell lines that were derived from these tumours had higher levels of intracellular glucose, glycolytic intermediates and components of the pentose phosphate pathway, whereas the TCA cycle was unaffected, which suggests that the autophagy defect in Trp53null PDA provides metabolic advantages for proliferation, and this is reminiscent of the Warburg effect.
Interestingly, the effect of autophagy inhibition in Kras G12V driven tumorigenesis in the lung (another OIS model 24 ) is distinct from the pancreas model. In the lung model, regardless of p53 status, autophagy deficiency diverts adenoma or adenocarcinoma into oncocytoma, . In TIS, active glucose uptake is maintained. The activity of pyruvate dehydrogenase (PDH) is positively and negatively regulated by PDH phosphatases (PDPs) and PDH kinases (PDKs), respectively. PDH is activated in cells in which senescence has been induced by oncogenic BRAF or RAS, although activation of PDH is accompanied by the induction of PDP2 and the suppression of PDK1 in BRAF-driven senescence but not in RAS-driven senescence 41 . Downregulation of malic enzymes (MEs) in both fibroblasts and some tumour cell lines induces senescence 50 . In mammals, there are three ME isoforms: the cytosolic, NADP Although it has been suggested that ME2 favours NAD + over NADP + as a cofactor (thereby primarily generating NADH), it has been shown that depletion of ME2 in cells in culture induces senescence that is accompanied by a reduction in the NADPH but not the NADH levels 50 . The relevance of the levels of MEs in OIS models is not clear (see main text for more information). Note that this figure represents a collective view that has been derived from recent studies using different models and should therefore not necessarily be generalized. Ac-CoA, acetyl-CoA; FA, fatty acid; PPP, pentose phosphate pathway; TCA, tricarboxylic acid. 
Inflammasomes
Cytosolic multiprotein innate immune complexes that assemble in response to various stimuli and that activate the pro-inflammatory serine protease caspase 1. Inflammasomes initiate innate immune responses by cleaving the inflammatory cytokines pro-interleukin-1ß (pro-IL-1ß) and pro-IL-18, leading to their activation and secretion.
Macrophages
Generally, M1-polarized macrophages inhibit cell proliferation and cause tissue damage, whereas M2-polarized macrophages promote cell proliferation and tissue repair. The M1 and M2 macrophages promote the T helper 1 (T H 1) and T H 2 cell responses, respectively.
Natural killer cells (NK cells).
A subgroup of white blood cells that is implicated in the killing of tumour or virus-infected cells. They are generally considered to be the cytotoxic lymphocytes of innate immunity owing to their lack of antigen-specific cell surface receptors, but they can also exert antibody-dependent cell cytotoxicity. which is a rare and predominantly benign tumour that is characterised by the accumulation of respirationdefective mitochondria 88 . Thus, in contrast to the pancreas model, autophagy deficiency (by autophagyrelated 7 (Atg7) knockout) suppresses Kras G12D driven lung cancer devel opment, even in the absence of Trp53; presumably, this is partially due to mitochondrial dysfunction. This is con sistent with the previous study from the same group that found that autophagy inhibition in nutrientstarved con ditions in cells that are 'addicted' to autophagy (particu larly cells expressing oncogenic KRAS and HRAS) can result in cell death accompanied by the accumulation of dysfunctional mitochondria 61 . Although the precise role of autophagy in these OIS models is still unclear, these studies highlight the complex link between autophagy and mitochondrial respiration. Autophagy also seems to be required for the increase in oxygen consumption during RASinduced senescence in mouse embryonic fibroblasts (MEFs), and TIS cells with hyperactive mitochondrial respiration die on inhi bition of autophagy 43 . Thus, to reconcile the apparently distinct roles for autophagy in tumorigenesis between the different tissues, it is tempting to speculate that autophagy might somehow regulate the balance between glycolysis and mitochondrial respiration, favouring the latter and, depending on the underlying metabolic stress, cells would develop either a glycolytic state or metabolic crisis 61 . It is also possible that the activated mitochondrial respiration reported in senescence models is, at least in part, dependent on intact autophagy.
Senescence and the extracellular environment
The SASP. The tumour suppressor function of senes cence has been mostly attributed to the lack of prolif erative capacity of senescent cells. However, increasing evidence, particularly from sophisticated mouse models, indicates that senescent cells actively communicate with neighbouring cells and the extracellular matrix through a plethora of secretory factors, including extracellular proteases, cytokines and chemokines, and growth factors. Such studies have revealed the functionality, as well as the dynamic longerterm fate, of senescent cells in vivo 89, 90 . The SASP adds enormous complexity to the implica tions of senescence in cancer. The nature of the SASP and its targets, and the overall downstream outcomes, vary considerably depending on the cellular context, the type of stress and the type of model used (FIG. 2) .
Various factors regulate the SASP, both at the tran scriptional and posttranscriptional levels, contributing to the diverse outputs of senescence 58, 59, [91] [92] [93] [94] [95] [96] . Importantly, SASP factors seem to form a hierarchical network, in which the signal is transduced and amplified. For exam ple, senescence was recently shown to be closely associ ated with inflammasomes, which have a central role in inflammation 93, 97 . This concept predicts the existence of a master regulator (or master regulators) of the SASP. Currently, proinflammatory cytokines, including IL1 and IL6, and their regulators have been proposed as major upstream regulators of the SASP, and inhibition of either of them results in the collapse of the cytokine network in culture 91, 93, 98, 99 . Some SASP components, such as matrix metallo proteinase 3 (MMP3) and plasminogen activator inhibitor 1 (PAI1), have long been used as markers of senescence 100, 101 . Although PAI1 has since been shown to be a positive effector of senescence 102 , some soluble fac tors, such as MMP3, were known to promote tumorigen esis in neighbouring premalignant epithelial cells through paracrine effects 103, 104 . Later studies reinforced the impor tance of the paracrine activities of the SASP, as IL6 and IL8 that are secreted from senescent cells promote tum origenesis in premalignant cells but not in normal cells. However, these same factors can facilitate senescence in a cellautonomous manner, thereby amplifying the pheno type 91, 92, 105 , and paracrine prosenescence factors, such as insulinlike growth factor binding protein 7 (IGFBP7), IL1 and transforming growth factorβ (TGFβ), were also identified 6, 93, 106, 107 , although the role of IGFBP7 as a paracrine senescence mediator in melanocytes is a matter of debate 108, 109 . Thus, it is conceivable that, in addition to its cellautonomous role, senescence could also confer a tumoursuppressive microenvironment during the early stages of tumorigenesis. However, this might be at the risk of a sudden change of senescence to a tumorigenic factor with the occurrence of 'senescenceescapers' (or de novo premalignant cells). These concerns would also be rel evant in attempting to use the induction of senescence as a cancer therapeutic goal, in which the SASP might drive the proliferation of surviving tumour cells 110 .
Clearance of senescent cells through an immune response.
Increasing evidence indicates that senescent cells can be eliminated through a SASPprovoked immune response, which involves both innate and adaptive immunity 111, 112 (FIG. 2) . The involvement of an immune response also extends the antitumour role of the SASP towards established transformed cells in some tumour models.
The first evidence for the clearance of senescent cells through an immune response came from a mouse model of liver carcinoma in which endogenous p53 could be restored by turning off Trp53targeted RNAi after tumours had been established 34 . Reexpression of endogenous p53 induced senescence, and the elimina tion of the senescent tumour cells was mediated by innate immune cells, including macrophages, neutrophils and natural killer cells (NK cells), albeit in mice that lacked an adaptive immune system. More recently, using a simi lar system, Iannello et al. 113 focused on the role of NK cells and described how they mediate the elimination of senescent tumour cells. They found that the recogni tion of retinoic acid early inducible 1ε (RAE1ε; a ligand expressed by tumour cells) by NKG2D (also known as KLRK1; an activating receptor expressed in all NK cells) is crucial for the elimination of senescent tumours. NKG2D has been implicated in the detection and elimi nation of transformed and virusinfected cells 114 . These ligands are induced in response to stress pathways that are associated with tumorigenesis and, indeed, RAE1ε in liver tumour cells was highly expressed before and after p53 restoration 113 . This raises an interesting possibility that senescence induction in only a subset of tumour cells would allow NK cells to kill not only senescent but also (FIG. 2) . The immunosuppressive nature of the tumour microenvironment is known to limit the capacity of immune cells to interact with and kill tumour cells 115 . Thus, it would be interesting to know whether, in addition to the increase in the level of chemoattractants, senescence induction in tumour cells also causes a reduc tion in the immunosuppressive factors that are produced by tumour cells and stromal cells.
Although the innate immune response is sufficient for the clearance of p53 reactivationinduced senescent cells from the liver, the adaptive immune system was also shown to have an important role during tumour senes cence in some mouse models 116 . For example, the deple tion of MYC in a mouse subcutaneous transplantation model of T cell acute lymphoblastic lymphoma (TALL), which carries a tetracyclineregulated MYC transgene, results in sustained tumour regression that is associated with senescence and apoptosis, in which an adaptive immune response (involving CD4 + T cells in particular) was required for senescence induction and sustained tumour regression, but not for apoptosis induction 116 . Although altered levels of several cytokines were evident on MYCdepletion, this study did not examine how the senescent cells were cleared.
A recent study, carried out by Kang et al. 112 , was used, which cannot induce senescence. Furthermore, similar to the TALL senescence model, CD4 + T cells are required for sustained tumour regression. Thus, this tumourassociated antigen (TAA)driven 'senescence surveillance' is an essential part of the tumour suppressor function of senescence.
Which aspect of senescence contributes to the immune clearance of premalignant cells in vivo? Although this is not clear, it is conceivable that a senescencespecific cock tail of immunomodulatory factors might be a key deter minant. Simian virus 40 (SV40) large Tantigendriven spontaneous hepatomas evade TAAdriven immune surveillance because of T cell tolerance 117 . Although large Tantigen is highly immunogenic, it binds to both p53 and RB, thereby efficiently blocking the senescence response. Interestingly, mice with large Tantigendriven hepatoma have high levels of TGFβ1, which effectively suppresses T cell function, but low levels of circulating interferonγ (IFNγ) 117 . Such a strong dominance of the function of TGFβ1 over IFNγ might contribute to the T cell tolerance of large Tantigen in these mice.
How general is senescence surveillance? Interestingly, in oncogenic Kras G12D driven PanIN, KRASG12D seems to be nonimmunogenic 115 . The reason for the contrast between the liver and pancreas models is unclear. However, it is noteworthy that in contrast to KRASG12D activation during embryogenesis in the PanIN model, Nras G12V was introduced directly into adult somatic cells in the liver. Thus, the KRASG12D 
Enterohepatic circulation
The circulation between the liver and the intestine. Bile acids and other substances excreted from the liver are reabsorbed by the enterocytes into the hepatic portal vein.
epitope might be recognised as a selfantigen and be sub ject to peripheral immune tolerance in the PanIN model. Interestingly, it was shown that pancreatic acinar cells, in which KRASG12V is activated during adulthood, show a low frequency of PanIN development and resistance to transformation, at least in part owing to OIS 118 . It is con ceivable that tumour susceptibility is different depending on the stage (or stages) of differentiation at which the cells are exposed to oncogenic stress. However, an alter native, highly speculative explanation may be that adult onset of KRASG12V activation in the pancreas may pro voke senescence immune surveillance. The same study also showed that episodic pancreatitis that is induced by caerulein (a decapeptide analogue of the gastrointestinal peptide hormone cholecystokinin) inhibited the OIS pro gramme, thereby facilitating malignant transformation in this model 118 . Further detailed characterisation of the immune response induced by either OIS or tissue dam age in these different models will be necessary. Of note, it seems that senescence arrest can be tumoursuppressive without any obvious involvement from senescence sur veillance: human melanocytic naevi (an OIS model), remain nonproliferative for decades without transfor mation into malignant melanoma 25 . These observations collectively underscore the diversity of the communica tion between senescent cells (or senescent cellstobe) and immune effector cells in different scenarios.
Senescence in the stroma. The paracrine activity of senes cent fibroblasts on epithelial cells was originally shown primarily in in vitro coculture or xenograft models, where fibroblasts that were induced to senesce in cul ture promoted the proliferation and invasiveness of their neighbouring premalignant or malignant epithelial cells 91, [103] [104] [105] 119 . However, Scott Lowe's group pioneered a mouse model to show stromal senescence in the in vivo setting 120 (FIG. 3) . During liver injury, quiescent hepatic stellate cells (HSCs) are activated to become prolifera tive and fibrogenic myofibroblasts, which contribute to liver fibrosis 121 . Using a wellestablished mouse model of liver fibrosis induced by chronic treatment with the liverdamaging agent carbon tetrachloride (CCl 4 ), they showed that activated HSCs become senescent, exhib iting a typical SASP, including the expression of extra cellular matrixdegrading enzymes and proinflammatory cytokines. The SASP also attracts innate immune cells that, in turn, eliminate the senescent HSCs and facilitate the resolution of fibrosis 94, 120 . Therefore, timely activation of HSCs and elimination of senescent activated HSCs are crucial for tissue integrity in this model. Although in this study it was not clear how activated HSCs become senes cent, a separate study showed that the matricellular pro tein CCN1 (also known as CYR61), which is secreted from damaged hepatocytes, can trigger senescence in activated HSCs 122 (FIG. 3) . CCN1 can also promote myofibroblast senescence, which is associated with the expression of anti fibrotic genes in the skin; thus, CCN1mediated stromal senescence might be involved in wound healing 123 . These data indicate that senescence in the context of some forms of tissue damage involves the spatiotemporal control of secreted protein levels, as well as the content of the SASP, which in turn modulates the senescence phenotype and dynamically regulates the surrounding tissue integrity, eventually contributing to the resolu tion of the lesion. Such a dynamic senescence process also seems to affect local tumorigenesis. In addition to fibrosis, senescent activated HSCs limit hepatocellular carcinoma (HCC) development in the presence of the chemical carcinogen diethylnitrosamine (DEN), at least in part through activating a 'classical' tumoursuppressive M1 phenotype of macrophages, which provides an anti tumour microenvironment and eventually eliminates senescent HSCs (FIG. 3) . Interestingly, senescence in acti vated HSCs and the subsequent SASPmediated activa tion of M1macrophages are mostly dependent on p53: Trp53deficient HSCs continue to proliferate, stimulate the tumourpromoting M2 macrophages and increase both cirrhosis and HCC development. Thus, p53 has a noncellautonomous tumoursuppressive role 94 , which was also proposed by an earlier study, in which p53 was shown to buffer the expression of tumorigenic SASP components in senescent cells, thereby restraining the tumorigenic microenvironment 105 . These studies exemplify the antitumour effects of stromal cell senescence and the accompanying SASP. However, another recent study suggests that the SASP of senescent HSCs can also promote tumorigenesis. Dietary or genetic obesity in mice can affect gut microbiota, and increased concentrations of the gut bacterial metabolite deoxycholic acid (DCA), which occurs during obesity, induces a SASP in HSCs via enterohepatic circulation. In the presence of the chemical carcinogen DMBA, DCA promotes HCC development in the obese mice 97 . Thus, in contrast to the CCl 4 induced liver damage model, DCA induced senescent HSCs in the obesity model seem to be tumorigenic. The reason behind the apparently opposing effects of senescent HSCs on HCC development is not known. The longterm fate of senescent HSCs and the nature of the immune response triggered by the SASP were not examined in the obesity model. However, it was noted that, unlike the CCl 4 treated mice, the obese mice did not develop fibrosis in the liver, suggesting that the nature of the tumour microenvironment may be substan tially different between these two models. The authors fed DCA to nonobese mice and DMBA failed to increase HCC development. Thus, some other obesityrelated pro tumorigenic factors may cooperate with senescent HSCs to facilitate the protumorigenic microenvironment. To better understand the switch in the impact of the SASP on tumorigenesis, it would be important to comprehen sively compare the SASP components of senescent HSCs between the two models.
Stromal senescence was more robustly demonstrated using p16reporter mice 124 . With a number of different cancer models in the p16reporter mouse, including transgenic autochthonous, transplanted and spontane ous tumours, the authors showed that early neoplastic events often induced stromal senescence much earlier than the point at which the tumours became palpable. Although further senescence validation using additional markers is necessary, these remarkably similar findings across different tumour models suggest that stromal Nature Reviews | Cancer Cytokine-mediated senescence. Recent studies have shown that some SASP components not only reinforce the senescence response in cells that are already primed for senescence but also induce senescence in normal neighbouring cells in a paracrine manner 93, 106 . However, these senescenceinducing soluble factors have different sources. For example, the chemokine GROα (also known as CXCL1), which is secreted from transformed cells, can induce senescence in stromal fibroblasts 125 . In an EμMyc lymphoma model, p53induced apoptosis of lymphoma cells led to the secretion of TGFβ1 by macrophages, which in turn induced senescence in lymphoma cells 36 . Thus, tumour apoptosis can locally provoke cytokinemediated senescence in this model. It should be noted that this study also reinforces the noncellautonomous tumour suppres sor role of p53, as mentioned above. Another example involves adaptive immunity and T H 1 cell cytokines that can directly drive cancer cells into senescence 126 . Using the classical SV40 large Tantigeninduced carcinogen esis model of pancreatic cancer, in which large Tantigen is expressed in pancreatic islets under the control of the rat insulin promoter (RIPTag2 mice 127 ), large Tantigen activated CD4
+ T H 1 cells (large TantigenT H 1 cells) have a tumoursuppressive role, which requires that the target tumour cells respond to both the IFNγ and tumour necro sis factor (TNF) signals that are produced by the large TantigenT H 1 cells 128 . Although large Tantigen binds to both RB and p53, it attenuates (rather than fully inacti vates) their activity; thus, their residual activities allow the RIPTag2 mice to show progressive tumorigenesis with only a small portion of islets developing invasive pancreatic cancer 127, 129 . Treatment of mice with large TantigenT H 1 cells in this model induces a cell proliferation arrest in the tumours and improves the survival of these mice 128 . The TAAexpressing islets treated with large TantigenT H 1 cells are functional (that is, they produce insulin) and therefore seemed to be in a state of tumour dormancy 128 . Although the relationship between tumour dormancy and senescence may be a matter of debate, the same group later showed that these cells were arrested owing to senes cence 126 . The senescence phenotype is dependent on the p16-RB pathway; thus, unlike the aforementioned large Tantigendriven hepatoma model, the residual RB activ ity seems to be sufficient for senescence induction in this model 129 . Importantly, if the tumour cells fail to respond to either IFNγ or TNF, large TantigenT H 1 cells do not only fail to suppress tumour growth, they promote tumour growth in RIPTag2 mice 128 . A link between tumour dormancy and the immune response has been observed in different experi mental tumour models 130 . For example, studies in a spontaneous mouse melanoma model suggest that dormancy in micrometastatic lesions is mediated by Figure 3 | Senescence in the stroma of the liver. During liver injury, quiescent hepatic stellate cells (HSCs) become activated. The HSCs become proliferative and fibrogenic myofibroblasts, which contribute to liver fibrosis by producing the extracellular matrix. Chronic liver damage (for example, from exposure to carbon tetrachloride (CCl 4 )) causes the activated HSCs to become senescent in a p53-dependent manner, exhibiting the typical senescence-associated secretory phenotype (SASP), including extracellular matrix-degrading enzymes and pro-inflammatory cytokines. The senescent activated HSCs thus limit excessive fibrosis (cirrhosis) and activate senescence surveillance through, for example, natural killer (NK) cells and antitumour M1 macrophages, and thereby limit the development of hepatocellular carcinoma (HCC) 94, 120 (part a). By contrast, in an obesity model, increased levels of the gut bacterial metabolite deoxycholic acid (DCA) provoked HSC senescence and the SASP promoted development of HCC 97 (part b). The matricellular protein CCN1, which is secreted from damaged hepatocytes, can also trigger senescence in activated HSCs, thereby limiting fibrosis 122 . immunosurveillance 131, 132 . In this model, tumour cells disseminate early during tumorigenesis, and these cells remain dormant for prolonged periods of time. Interestingly, cytostatic CD8 + T cells suppress the expan sion of the disseminated tumour cells 132 . Precisely how CD8 + T cells induce tumour dormancy is not shown in this model; however, CD8 + T cells also secrete cyto static cytokines, including IFNγ and TNF. Thus, the combination of IFNγ and TNFinduced senescence, in particular, might widely contribute to tumour control. Consistently, Braumüller et al. 126 confirmed that IFNγ and TNF induce senescence in several different cancers, both in vitro and in vivo.
Chronic inflammation is generally a risk factor for tum origenesis 133 ; however, psoriasis (an immunemediated cutaneous chronic inflammatory disease) is associated with a reduced risk for cancer 134 . It is suspected that this might be because of senescence 135 . The development of psoriatic plaques is accompanied by activation of CD4 + T cells and other immune cells, which provide a plethora of cytokines and chemokines, including TNF and IFNγ
136
. Here also, a TNF and IFNγ cocktail might provide a dominant tumour suppressor activity through cytokineinduced senescence.
Concluding remarks
Recent advances in our understanding of senescence biol ogy have substantially extended the known pathophysi ological roles of senescence. These studies suggest that senescence is a more widespread phenomenon than was previously thought
. The functional association of senescence with other regulatory phenotypes, such as mitochondrial metabolism and the immune response, requires further study. For example, metabolic interme diates of the TCA cycle affect epigeneticmediated con trol of gene expression by regulating the modification of histones and DNA 137, 138 . These pathways might well be altered in senescent tumour cells and stromal cells. Although in this Review we have treated carbohydrate metabolism as a cellautonomous effector, it is conceiv able that metabolic intermediates from different tissue compartments can transduce signals and nutrients to each other. Indeed, it has been proposed that the lactate extruded from glycolytic tumour cells may be taken up by tumour cells (and potentially senescent cells) undergoing oxidative phosphorylation to fuel the TCA cycle 139 . Senescent cells are, by definition, irreversibly arrested; however, in the senescence immunosurveillance model, senescence per se may not be a very efficient tumour suppressor, at least in some tumour models. The anal ogy between senescence and dormancy in some tumours also implies that the in vivo senescencelike arrest may be unstable, because dormant tumour cells can reproliferate after long periods of time 130, 140 . It is possible that a rare sto chastic event of senescence escape occurs, in some cases facilitated by a SASP, during the course of tumorigenesis. Much like dormant cells, senescent cells are resistant to apoptosis or mitotic catastrophe upon chemotherapy; thus, if senescent tumour cells are not eliminated, the sustained expression of protumorigenic cytokines can lead to a worse outcome 110 . It is also possible that the het erogeneity and complexity of the senescence phenotype may confer a range of senescence intensity or quality 4 ; thus, in some contexts or tissues, coupling a stable cell cycle arrest with the eventual clearance of the senescent cells is necessary to limit tumorigenesis.
Such a diverse senescence response is also relevant when considering senescence as a therapeutic option. For example, the outcome of endogenous p53 reactiva tion can be senescence and/or cell death, depending on the tumour type 35, 141, 142 . Even in the same tissue, the same triggers can either suppress (by inducing senes cence) or promote tumorigenesis, as in the case of cytokineinduced senescence 128, 143 . The partial induc tion of senescence in tumours could eradicate or exacerbate the tumours 110, 113 . The mechanisms for the selective elimination of senescent cells -which may be immunemediated or nonimmunemediated -need to be explored further. Researchers have just started to accumulate examples of the highorder communication of senescence with the microenvironment in several in vivo models, but our current knowledge suggests that carefully individualized medical indications need to be considered when targeting senescence effectors for cancer therapy. A more detailed understanding of the integrity of the SASP, in terms of both the expression of the components and its functional networks, would help us to exploit senescence for optimal tumour suppression.
